Tag Archive | "biosimilars"

Hospira and Pfenex partner for ophthlamics biosimilar

Tags: , , ,

Pfenex and Hospira have entered into an agreement to exclusively develop and commercialize for worldwide sales PF582, Pfenex's biosimilar candidate to Genentech's LUCENTIS (ranibizumab injection). Read the full story

Baxter and Coherus are pharma partners for biosimilar development

Tags: , , , ,

Baxter International, a big pharma company,  and Coherus Biosciences are pharma partners by entering into an exclusive collaboration to develop and commercialize a biosimilar to etanercept for Europe, Canada, Brazil and certain other markets Read the full story

Teva and pharma partners Lonza discontinue joint venture

Tags: , , ,

Pharma partners, Teva Pharmaceutical and Lonza Group, have decided to discontinue their collaboration for the development, manufacturing and marketing of biosimilars. Read the full story

Pharmaceutical trends: Samsung eyes generic biological medicines

Tags: , ,

Samsung, the South Korean conglomerate, plans to launch generic  versions of biological medicines by 2015 at half the current western prices,  as it gears up to challenge US and European pharmaceutical  companies Read the full story

Boehringer blueprints new division to tackle biosimilar development

Tags: , , ,

Boehringer Ingelheim is to tap into the growing interest in biosimilars with the creation of a division dedicated to that market.  Read the full story

Multinationals eager to jump into the mulibillion-dollar biosimilar business

Tags: , ,

What have South Korean smartphone maker Samsung SAGR.UL, petrochemicals group Hanwha Chemical, Indian industrial giant Reliance and Japanese digital camera maker Fujifilm got in common?  Read the full story

Biosimilar market will reach $3.7bn in 2015

Tags: ,

More than 30 branded biologics with sales of $51bn set to lose patent exclusivity between 2011 and 2015, and uptake of biosimilar versions will drive market growth. Read the full story

Biosimilars in the EU: delivering the goods?


In January 2009, leading pharmaceutical experts attended the 2009 Forum Institute seminar on biosimilars, and the challenges involved in their successful development and launch. While the main focus of the meeting the biosimilars market in the EU, it was widely agreed that developments in the US, and President Obama's handling of the generic biotech issue, will be the defining issue of 2009 and beyond. Read the full story